Our results motivate future clinical trials to evaluate whether sodium-glucose cotransporter 2 inhibitors, a well-known anti-diabetic medication that reduces HF hospitalization in type 2 diabetes, should be used in individuals with type 1 diabetes and central obesity. Here, SLC5A2 is linked to Abdominal obesity.